TRUQAP (capivasertib) tablets
TRUQAP is an AKT inhibitor that works by disrupting signals from the AKT protein and other proteins along its pathway that can drive cancer growth. TRUQAP is taken with the hormone therapy fulvestrant. FDA approved capivasertib (brand name TRUQAP) is not (yet) registered or available in India but on request Indian patient can buy TRUQAP at the lowest price.
Home | capivasertib tablets
Submit a request to access drug used to treat, diagnose or prevent serious or life-threatening conditions.We’ll get back to you within 1 business days!
For Indian Patient Enquiry under NPP.
For any urgent inquiries or assistance needed, please reach out to our Support Team. Rest assured, we will respond within 24 hours, from Monday to Saturday, during the hours of 9:00 A.M to 18:00 PM.
TRUQAP (capivasertib) tablets
Capivasertib, used in combination with fulvestrant (Faslodex), is indicated for adults with hormone receptor-positive, human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations, as detected by an FDA-approved test...
TRUQAP is a kinase inhibitor indicated, in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or
metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations as detected by an FDA-approved test following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy.
Capivasertib, sold under the brand name Truqap, is an anti-cancer medication used for the treatment of breast cancer. It is taken by mouth.
The most common adverse reactions include diarrhea, cutaneous adverse reactions, increased random glucose, decreased lymphocytes, decreased hemoglobin, increased fasting glucose, nausea, fatigue, decreased leukocytes, increased triglycerides, decreased neutrophils, increased creatinine, vomiting, and stomatitis.
In November 2023, capivasertib was approved in the United States for people with hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer when used in combination with fulvestrant. The US Food and Drug Administration (FDA) considers it to be a first-in-class medication.
Drug (Brand / Generic): TRUQAP / capivasertib
Current Indication: breast cancer
Approval Date: 2023
Tablets: 160 mg and 200 mg
Find Reference Updates
- TRUQAP (capivasertib) tablets And Usage, Dosage And Administration, Dosage Forms And Strengths and Drug Interactions.
- FDA approves capivasertib with fulvestrant for breast cancer
- Truqap Plus Fulvestrant Approved for HR-Positive Advanced Breast Cancer
- AstraZeneca’s Truqap plus Faslodex receives FDA approval for advanced breast cancer
For more highlights of prescribing information regarding Indications and usage, dosage and administration, dosage forms and strengths, patient counseling information and medication guide. Click Here
Alleviare Life Sciences
About Us
Alleviare Life Sciences Pvt. Ltd. (India) serves as a facilitator for medical and pharmaceutical products, commencing its operations in 2005. Headquartered in Delhi, India, Alleviare operates nationwide, providing a range of comprehensive services to patients, doctors, hospitals, and government healthcare facilities.
Our specialization lies in facilitating access to medicines, leveraging our expertise in sourcing and providing documentation assistance for programs such as Named Patient Program, Managed Access Program, and Early Access Program. We take pride in ensuring smooth and efficient access to medications for those who require them.
Alleviare India is a trusted pharmaceutical access facilitator in India, aligned with Good Distribution Practice (GDP) standards. We provide specialized support to help patients and healthcare professionals access TRUQAP (capivasertib) tablets, an internationally approved therapy.
Where TRUQAP is not commercially available in India, we facilitate access through regulated pathways such as the Named Patient Supply (NPS) framework. Each request is carefully managed in compliance with applicable regulations and requires a valid prescription and, where necessary, import authorization.
Get Access to FDA approved capivasertib (brand name TRUQAP) in India.
We can help patients access approved TRUQAP (capivasertib) tablets in the following cities across India – Ahmedabad, Bangalore, Surat, Kolkata, Pune, Indore, Nagpur, Agra, Kanpur, Patna, Coimbatore, Kochi, Delhi, Gurugram, Amaravati, Itanagar, Dispur, Patna, Raipur, Panaji, Gandhinagar, Chandigarh, Shimla, Ranchi, Bengaluru, Thiruvananthapuram, Bhopal, Mumbai, Imphal, Shillong, Aizawl, Kohima, Bhubaneswar, Jaipur, Gangtok, Chennai, Hyderabad, Agartala, Lucknow, Dehradun, Gairsain. Aizawal, Aurangabad, Barshi, Cachar, Dibrugarh, Karungapally, Kollam, Meghalaya, Mizoram, Sikkim, Pondichery, Punjab, Tripura, New Delhi, Agra, Gurugram, Alwar, Mathura, Panipat, Faridabad, Noida, Sonipat, Rohtak, Karnal, Ambala, Ghaziabad.
TRUQAP (capivasertib) Tablets – Sourcing & Access Support
Alleviare India provides assistance in facilitating access to TRUQAP (capivasertib) tablets, a prescribed oncology medication, through trusted international supply channels. We support patients and healthcare providers in identifying appropriate supply options for medicines that may have limited local availability, in accordance with applicable regulations.
Access is provided only against a valid prescription, and services are offered under the Named Patient Supply (NPS) framework. Alleviare India may also assist in connecting with authorized supply channels where appropriate.
Pricing & Availability in India
For information on the availability and indicative pricing of TRUQAP (capivasertib) tablets, please contact us directly.
The cost of the medicine is determined by the manufacturer. Additional charges may include Named Patient support service fees, shipping costs, and applicable local taxes, in accordance with regulatory requirements.
Is TRUQAP available in India?
Meet Our Medicine Access Expert for availability of Truqap medications.
At Alleviare, we prioritize transparency while supporting patients, healthcare professionals, and institutions in accessing genuine medicines through trusted global sources in Canada, Europe, the USA, and Australia. We provide tailored assistance to facilitate access to prescribed therapies, including those not readily available locally, in full compliance with applicable regulatory requirements.
Access is facilitated under the Named Patient Supply (NPS) framework. We also offer guidance on the availability and indicative pricing of prescribed medications across major cities in India, including Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, and Pune.
Medicine: TRUQAP (capivasertib) tablets (subject to prescription and regulatory guidelines)
Start Your Access Journey
Email: info@alleviareindia.com, Mobile: +91 9818274099 / 9289711088
Is capivasertib available in India?
Yes, FDA approved capivasertib (brand name TRUQAP) is not (yet) registered or available in India but on request Indian patient can buy TRUQAP at the lowest price.
What documents are required to import TRUQAP to India?
To import TRUQAP (capivasertib), patients or government hospitals can place an order on behalf of the patients. The following documentation is required for the import process:
- Valid prescription from a qualified doctor.
- Patients’ diagnostic reports.
- Patients’ ID proof issued by the Government of India.
The order will be confirmed only after the receipt of the following:
- Valid prescription from the doctor.
- Import permit, if applicable.
Please ensure that all the necessary documentation is provided to confirm the order.